Trial Profile
An Open-Label Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous (SC) Versus Intravenous (IV) Administration of CINRYZE in Adolescents and Adults With Hereditary Angioedema (HAE)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Complement C1 inhibitor protein (Primary) ; Complement C1 inhibitor protein (Primary)
- Indications Hereditary angioedema
- Focus Adverse reactions
- Sponsors Shire
- 23 Apr 2014 New trial record